| Identification | Back Directory | [Name]
4-fluoro-3-((4-hydroxypiperidin-1-yl)sulfonyl)-N-(3,4,5-trifluorophenyl)benzamide | [CAS]
1445790-55-5 | [Synonyms]
4-fluoro-3-((4-hydroxypiperidin-1-yl)sulfonyl)-N-(3,4,5-trifluorophenyl)benzamide
Benzamide, 4-fluoro-3-[(4-hydroxy-1-piperidinyl)sulfonyl]-N-(3,4,5-trifluorophenyl)- | [Molecular Formula]
C18H16F4N2O4S | [MOL File]
1445790-55-5.mol | [Molecular Weight]
432.39 |
| Hazard Information | Back Directory | [Description]
NVR 3-778 is the first capsid assembly modulator (CAM) that has demonstrated antiviral activity in hepatitis B virus (HBV)-infected patients. NVR 3-778 inhibited the generation of infectious HBV DNA-containing virus particles with a mean antiviral 50% effective concentration (EC50) of 0.40?μM in HepG2.2.15 cells. The antiviral profile of NVR 3-778 indicates pan-genotypic antiviral activity and a lack of cross-resistance with nucleos(t)ide inhibitors of HBV replication. | [Uses]
NVR 3-778 is a first-in-Class and oral bioavailable HBV CAM (capsid assembly modulator) belonging to the SBA (sulfamoylbenzamide) class, with anti-HBV activity[1]. | [in vivo]
NVR 3-778 (1.5?mg/kg; i.g.) displays the mean Cmax and AUC0–inf values of 0.56?μg/ml and 3.50?μg·h/ml, respectively, in dogs following oral administration. And the mean oral bioavailability is determined to be 84.6%[1].
| Animal Model: | Dogs[1] | | Dosage: | 1.5?mg/kg (Pharmacokinetic Analysis) | | Administration: | Oral gavage | | Result: | The mean Cmax and AUC0–inf values are 0.56?μg/ml and 3.50?μg·h/ml and the oral bioavailability is 84.6%. |
| [References]
[1] Lam AM, et al. Preclinical Characterization of NVR 3-778, a First-in-Class Capsid Assembly Modulator against Hepatitis B Virus. Antimicrob Agents Chemother. 2018 Dec 21;63(1). DOI:10.1128/AAC.01734-18 |
|
|